OXGN - OXiGENE, Inc. ( NASDAQ:OXGN)

[the volture]

Oxgn-nasdaq-biotech

RIMBALZA oppure no????

recuperato il supporto di breve a 3,33,,sopra a 3,5 va a 3,8

grafico daily

 

[the volture]

ieri a 3,32, incrocio ema 10 su rsireverse grafico 40 minuti,,,se arriva a 3,61 ci sono buoni margini di salita

 

[Ianuzzo]

Oxgnok!ok!ok!

 

[the volture]

si è un po sgonfiata..ma perche oggi saliva???


news non ne vedo

 

[Ianuzzo]

Secondo me questo vale molto di più di Snss , con circa 80 mln di azioni , 35 +20 mln di contanti post merger , farmaci in fase II e fase II , uno stabilimento per la produzione di vaccini , gli insider che continuano ad acquistare azioni .

www.mffais.com

 

[Ianuzzo]

http://www.secform4.com/insider-trading/908259.htm

 

[Liuyr]

Chi sa qualcosa su questa?

 

[cervellofine]

http://seekingalpha.com/article/205427-three-promising-small-cap-cancer-plays?source=yahoo

http://finance.yahoo.com/news/OXiGENE-Reports-First-Quarter-pz-1996835478.html?x=0&.v=1

........

"In the first quarter, OXiGENE made good progress toward our goals of strengthening our company, focusing clinical resources on our most promising product candidates, reducing cash utilization and extending our cash runway," said Peter J. Langecker, M.D., Ph.D., OXiGENE's Chief Executive Officer. "We look forward with enthusiasm to presenting data on our high-priority clinical programs at the American Society of Clinical Oncology (ASCO) annual meeting, including safety and efficacy data from our Phase 2 trial of ZYBRESTAT(TM) in non-small cell lung cancer (NSCLC) and data from our Phase 1b trial of OXi4503 in solid tumors. We believe that today OXiGENE has a strong pipeline and a competitive position in the field of vascular disrupting agents in cancer, and we are the only company clinically evaluating a vascular disrupting agent in an ophthalmologic indication. We anticipate multiple value-creating opportunities in 2010, including the potential to establish industry partnerships that will enhance our ability to deliver on the promise of our programs."

..........

dentro a 1$

 

[cervellofine]

tiene decentemente il prezzo in una giornata con più ombre ke luci, range 0,97-1,03

volumi leggermente sopra la media, confortanti, ci si affida alla fortuna e a qualke buona news che potrebbe arrivare dal meeting Asco in programma a giugno, lo scorso anno ci fù un bel run, sarei molto soddisfatto ne mettesse in atto sl un terzo si fà per dire

stop 0,92 soggettivo, il chart chiama alla prudenza

 

[taba]

entrato ieri a 0,98 ,, in attesa dell'asco

 

[taba]

OXiGENE Announces Clinical Data to be Presented at the 2010 Annual Meeting of the American Society of Clinical Oncology

SOUTH SAN FRANCISCO, Calif., May 18, 2010 (GlobeNewswire via COMTEX) -- OXiGENE, Inc. /quotes/comstock/15*!oxgn/quotes/nls/oxgn (OXGN 0.96, -0.03, -3.03%) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that data from clinical trials involving its vascular disrupting agent (VDA) product candidates, fosbretabulin (ZYBRESTAT(TM)) and OXi4503, will be presented in two posters at the upcoming 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, June 4-8, 2010. In addition, two additional posters describing fosbretabulin and OXi4503 trial designs will be presented in the newly-created "Trials in Progress" poster session. OXiGENE will release a summary of results immediately after they are presented.
ZYBRESTAT Presentation Details:
#7587: Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin, paclitaxel and bevacizumab in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): The FALCON trial. Poster presentation by Edward Garon, M.D. on Sunday, June 6, 2010, General Poster Session: Lung Cancer, S Hall A2, 8:00 am-12:00 pm.
#2594: Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors. Poster presentation by Martin Zweifel, M.D. on Monday, June 7, 2010, Developmental Therapeutics: Molecular Therapeutics, S Hall A2, 8:00 am-12:00 pm.
#TPS164: A multicenter, open-label phase Ib/II study to assess the safety and clinical activity of intravenous combretastatin A1 diphosphate (OXi4503) as monotherapy in subjects with primary or secondary hepatic tumor burden. Poster presentation by Paul N. Mainwaring, M.D. on Monday, June 7, Trials in Progress Poster Session, S Hall A2, 8:00 am-12:00 pm.
#TPS147: A pilot study of fosbretabulin with bevacizumab in recurrent high-grade gliomas. Poster presentation by Ramin Altaha, M.D., on Monday, June 7, Trials in Progress Poster Session, S Hall A2, 8:00 am-12:00 pm.
About ZYBRESTAT (fosbretabulin)
ZYBRESTAT is being evaluated in a Phase 2 study of patients with non-small cell lung cancer and other clinical trials. OXiGENE believes that ZYBRESTAT is poised to become an important product in a novel class of small-molecule drug candidates called vascular disrupting agents (VDAs). Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has demonstrated potent and selective activity against tumor vasculature, as well as clinical activity against ATC, ovarian cancer and various other solid tumors.
About OXi4503
OXi4503 (combretastatin A1 di-phosphate / CA1P) is a dual-mechanism vascular disrupting agent (VDA) that is being developed in clinical trials for the treatment of solid tumors. Like its structural analog, ZYBRESTAT(TM) (fosbretabulin / CA4P), OXi4503 has been observed to block and destroy tumor vasculature, resulting in extensive tumor cell death and necrosis. In addition, preclinical data indicate that OXi4503 is metabolized by oxidative enzymes (e.g., tyrosinase and peroxidases), which are elevated in many solid tumors and tumor white blood cell infiltrates, to an orthoquinone chemical species that has direct cytotoxic effects on tumor cells. Preclinical studies have shown that OXi4503 has (i) single-agent activity against a range of xenograft tumor models; and (ii) synergistic or additive effects when incorporated in various combination regimens with chemotherapy, molecularly-targeted therapies (including tumor-angiogenesis inhibitors), and radiation therapy. OXi4503 is currently being evaluated as a monotherapy in a Phase 1 dose-escalation trial in patients with advanced solid tumors and in patients with hepatic tumor burden.

 

[diedicar]

entrato ieri a 0,98 ,, in attesa dell'asco

in gran watch, penso di entrare oggi. titolo in sordina, mi piace

 

[diedicar]

entrato oggi, col pessimo propositoi di rifarmi di agen... però ho scovato questo:
http://www.sec.gov/Archives/edgar/data/908259/000092963810000363/0000929638-10-000363-index.htm
titolo sui minimi....

 

[LOROCIU65]

entrato oggi, col pessimo propositoi di rifarmi di agen... però ho scovato questo:
http://www.sec.gov/Archives/edgar/data/908259/000092963810000363/0000929638-10-000363-index.htm
titolo sui minimi....

06/04 SNTS FDA Decision
06/04 CLDX Clinical Trial
06/04 OXGN Clinical Trial
06/04 IMMU Clinical Trial
06/04 MYRX Clinical Trial
06/04 PGNX FDA Decision
06/04 CYCC Clinical Trial
06/06 PKNGF FDA Decision
06/06 SNSS Clinical Trial
06/09 MELA FDA Decision
06/11 QCOR Clinical Trial
06/30 ABIO Clinical Trial
06/30 ANTH Clinical Trial
06/30 YMI Clinical Trial
06/30 GENT FDA Filling
06/30 ANDS Clinical Trial
06/30 NBY Clinical Trial
06/30 DARA Clinical Trial
06/30 ATHX Clinical Trial
06/30 SQNM Clinical Trial
06/30 RNN Clinical Trial
06/30 INO Clinical Trial
06/30 CBMX Clinical Trial
06/30 OMER Clinical Trial
06/30 AVNR FDA Filling
06/30 KERX Clinical Trial
06/30 CYTR Clinical Trial
06/30 ACCP Clinical Trial
06/30 BIEL 510K clearance
06/30 SNTA Clinical Trial
06/30 RPRX FDA response
06/30 PVCT Clinical Trial
06/30 ARRY Clinical Trial
06/30 SNGX Clinical Trial
06/30 TTHI Clinical Trial
06/30 ZIOP Clinical Trial

JULY

07/07 OSUR FDA decision
07/15 VVUS Advisory Panel Meeting
07/15 BLUD 510k Clearance
07/24 ESALY FDA Decision
07/25 ABT FDA Decision
07/31 ATEC Clinical Trial
07/31 INO Clinical Trial
07/31 NVAX Clinical Trial
07/31 GSK Advisory Panel
07/31 CBLI Clinical Trial
07/31 TRGT Clinical Trial
07/31 CVM Clinical Trial
07/31 VICL Clinical Trial
07/31 ISTA Clinical Trial
07/31 DSCI Clinical Trial
07/31 SGEN Clinical Trial
07/31 KOOL 510k Clearance
07/31 POZN EU Decision (Estimated)

 

[LOROCIU65]

messo gettone di presenza..

 

[gigante]

vi devo ingessare le dita anche a voi

 

[taba]

in gran watch, penso di entrare oggi. titolo in sordina, mi piace

io oggi ho mediato..

 

[diedicar]

+7 in pre, meglio che niente

 

[LOROCIU65]

..e' oro colato di sti tempi...

 

[diedicar]

ho letto l'abstract, è buono ma non da strapparsi i capelli, però guarda cosa ha fatto a maggio l'anno scorso...